IV Immunoglobulin May Cut Infection Risk of Anti-BCMA Agents for Myeloma
(MedPage Today) -- Use of intravenous immunoglobulin (IVIg) may substantially reduce the risk for severe infections in multiple myeloma patients treated with an anti-B-cell maturation antigen (BCMA) bispecific antibody, a small retrospective study... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 30, 2023 Category: Hematology Source Type: news
Anti-TIGIT Plus Immunotherapy 'Promising' in NSCLC, Esophageal Cancer
(MedPage Today) -- Combination treatment with an investigational anti-TIGIT drug plus a PD-L1 inhibitor was well tolerated and demonstrated promising activity in patients with metastatic non-small cell lung cancer (NSCLC) and esophageal cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2023 Category: Hematology Source Type: news
Cancer Drug Shortages for Kids; Pharma Agrees to Price Talks; Catch-Up on Screening
(MedPage Today) -- Despite ongoing efforts to overcome shortages of cancer drugs, many hospitals report critically low supplies of drugs to treat leukemia and lymphoma in children. (NBC News)
Reluctantly, AstraZeneca, Bristol Myers Squibb, and... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 28, 2023 Category: Hematology Source Type: news
Study Confirms Better Survival for HPV-Positive Cervical Cancer
(MedPage Today) -- Cervical cancer associated with detectable human papillomavirus (HPV+) RNA or DNA had significantly better outcomes, including survival, a large meta-analysis of published studies showed.
Patients who tested positive for HPV... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 27, 2023 Category: Hematology Source Type: news
Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia
(MedPage Today) -- Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with hairy cell leukemia in a small... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 26, 2023 Category: Hematology Source Type: news
Reduced Mortality Seen in Cancer Survivors Who Meet Exercise Guidelines
(MedPage Today) -- Exercise consistent with national guidelines was associated with a significant reduction in all-cause mortality in long-term cancer survivors, a pan-cancer analysis showed.
In a study involving 11,480 survivors, guideline-concordant... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 23, 2023 Category: Hematology Source Type: news
TikTok Dinged for Misinformation; BRCA Risk Overestimated; Cheers for Oncology
(MedPage Today) -- Social media site TikTok has become a common source of misinformation about gynecologic cancers. (Ohio State University Comprehensive Cancer Center, Gynecologic Oncology)
PGA Tour golfer Gary Woodland recently had surgery to... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 21, 2023 Category: Hematology Source Type: news
Ultrasound May Help Early Breast Cancer Patients Avoid SLNB
(MedPage Today) -- Omitting axillary surgery completely in early breast cancer patients with a negative preoperative axillary ultrasound resulted in similar outcomes compared with sentinel lymph node biopsy (SLNB), and did not appear to affect... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 21, 2023 Category: Hematology Source Type: news
Cisplatin Shortage Eases; Air Pollution Linked to Breast Cancer; Pap Test Confusion
(MedPage Today) -- The nation's supply of the widely used cancer drug cisplatin has almost returned to pre-shortage levels. (Becker's Hospital Review)
The FDA announced a new and updated indication for temozolomide (Temodar) in anaplastic astrocytoma... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 15, 2023 Category: Hematology Source Type: news
Individualized SABR for Lung Tumors Yields Low Recurrence Rates
(MedPage Today) -- Individualizing stereotactic ablative radiotherapy (SABR) dose and fractionation according to tumor size, location, and histological characteristics was associated with "excellent" local control and low rates of severe toxic... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 14, 2023 Category: Hematology Source Type: news
IMRT Best for Locally Advanced NSCLC, Study Suggests
(MedPage Today) -- SINGAPORE -- Intensity-modulated radiation therapy (IMRT) should be the radiation technique of choice for unresectable locally advanced non-small lung cancer (NSCLC), a secondary analysis of a randomized trial suggested.
In... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2023 Category: Hematology Source Type: news
Novel Antibody-Drug Conjugate Shows Efficacy in Advanced EGFR-Mutated NSCLC
(MedPage Today) -- SINGAPORE -- Treatment with the novel antibody-drug conjugate patritumab deruxtecan (HER3-DXd) after progression with an EGFR tyrosine kinase inhibitor (TKI) and platinum-based chemotherapy resulted in "clinically meaningful... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2023 Category: Hematology Source Type: news
Study Questions Use of Aggressive Surgery in Early Mesothelioma
(MedPage Today) -- SINGAPORE -- Extended pleurectomy/decortication combined with platinum and pemetrexed chemotherapy was associated with worse outcomes in patients with resectable mesothelioma compared with chemotherapy alone, according to a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2023 Category: Hematology Source Type: news
Adding First-Line Chemo Boosts PFS in EGFR-Mutant Lung Cancer
(MedPage Today) -- SINGAPORE -- Treatment with osimertinib (Tagrisso) plus chemotherapy reduced the risk of disease progression or death by 38% compared with osimertinib monotherapy in patients with advanced EGFR-mutant non-small cell lung cancer... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 12, 2023 Category: Hematology Source Type: news
First-Line Triplet Yields 'Striking' OS Result in Extensive-Stage SCLC
(MedPage Today) -- SINGAPORE -- Adding the investigational combination of PD-L1 inhibitor benmelstobart and antiangiogenic tyrosine kinase inhibitor anlotinib to first-line chemotherapy significantly improved survival in extensive-stage small... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 11, 2023 Category: Hematology Source Type: news
